| Systematic (IUPAC) name | |
|---|---|
| Phosphoric acid mono-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxy-phenyl)-vinyl]-phenyl} ester | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| ATC code | ? |
| PubChem | CID 5351387 |
| Synonyms | CA4P CA4PD |
| Chemical data | |
| Formula | C18H21O8P |
| Mol. mass | 396.32 g/mol (exact mass : 396.097404) |
| (what is this?) (verify) |
|
Combretastatin A-4 phosphate (and its disodium salt) is a microtubule destabilizing drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis. It is a derivative of combretastatin.
Combretastatin A-4 phosphate is a prodrug. In vivo, it is dephosphorylated to its active metabolite, combretastatin A-4.[1]